Outcomes of <scp>BCG</scp> vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer
Pietro Scilipoti(Vita-Salute San Raffaele University), Marco Moschini(Vita-Salute San Raffaele University), Francesco Soria(Medical University of Vienna), Wojciech Krajewski(Wroclaw Medical University), David D‘Andrea(Medical University of Vienna), Riccardo Mastroianni(Surgical Specialties (Canada)), Ekaterina Laukhtina(Comprehensive Cancer Center Vienna), Paolo Gontero(Fondazione Ricerca Molinette), Aleksander Ślusarczyk(Medical University of Warsaw), Luca Afferi(Universitat Autònoma de Barcelona), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Andrea Gallioli(Puigvert Foundation), Javier Aranda(Complejo Hospitalario de Cáceres), Keiichiro Mori(Jikei University School of Medicine), Andrea Salonia(Vita-Salute San Raffaele University), Mattia Longoni(Vita-Salute San Raffaele University), Giuseppe Simone(Istituti di Ricovero e Cura a Carattere Scientifico), José Luis Rodríguez Elena(Complejo Hospitalario de Cáceres), Simone Albisinni(University of Rome Tor Vergata), Francesco Montorsi(Vita-Salute San Raffaele University), Mario de Angelis(IRCCS Ospedale San Raffaele), Gautier Marcq(Centre National de la Recherche Scientifique), Morgan Rouprêt(Sorbonne Université), J. Caño Velasco(Hospital General Universitario Gregorio Marañón), José Daniel Subiela(Universidad de Alcalá), Renate Pichler(Innsbruck Medical University), Rodolfo Hurle(IRCCS Humanitas Research Hospital), Andrea Necchi(Vita-Salute San Raffaele University), Benjamin Pradere(Hôpital de la Croix-Rousse), Paolo Zaurito(Vita-Salute San Raffaele University), A. Lafuente Puentedura(Hospital General Universitario Gregorio Marañón), Katharina Oberneder(Comprehensive Cancer Center Vienna), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Francesco Del Giudice(Sapienza University of Rome), Shahrokh F Shariat(Cornell University), Roberto Contieri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Piotr Radziszewski(Medical University of Warsaw), Laura S. Mertens(Oncode Institute)
Cited by 12
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k